Volition
@VolitionRx
Followers
1K
Following
471
Media
361
Statuses
2K
We are dedicated to revolutionizing the diagnosis and monitoring of life-altering diseases by advancing the science of epigenetics.
Henderson, Nevada, USA
Joined January 2011
Hear from Volition's Group Chief Executive Officer, Cameron Reynolds regarding their Third Quarter Finanical Results & Business Update
2
0
2
Q3 2025 results out now: https://t.co/RpohCLx2Ne "We believe that our positive emerging clinical evidence supports the broad applicability of our Nu.Q® technology in critical areas such as cancer and sepsis, including as a biomarker of interest to epigenetic drug development, an
0
0
0
Our Q3 2025 Financial Results and Business Update call will take place this Friday. Find out more: https://t.co/b0ob6xobtB
0
1
0
November is #PetCancerAwarenessMonth, an initiative dedicated to informing pet owners and veterinary professionals about the prevalence of cancer in companion animals. While often underestimated, cancer is one of the leading causes of death in dogs and cats. Yet, with early
0
0
0
ELBS General Assembly 2025: our colleagues introduced our Nu.Q® Discover Services and presented the preliminary results of our ongoing Lung Cancer study. The meeting highlighted the remarkable efforts being made to develop and promote liquid biopsy to bring it as a routine tool
0
1
2
#ICYMI: Our GenomeWeb Nu.Q® Discover webinar is now available ON DEMAND Beyond the Genome: Measuring Epigenetic Modifications Across Matrices for Biomarker and Drug Discovery 🔗:
event.on24.com
Wednesday, October 08, 2025 at 11:00 AM Eastern Daylight Time.
0
0
0
GenomeWeb Nu.Q® Discover webinar: now available ON DEMAND Beyond the Genome: Measuring Epigenetic Modifications Across Matrices for Biomarker and Drug Discovery 🔗:
0
0
0
NEWS: Volition donated Nu.Q® Vet Cancer Tests to HOPE Animal-Assisted Crisis Response Dogs at Hope AACR annual meeting. Dr. Michelle Silver, DVM, DACVIM – Oncology, commented: “Ensuring our crisis canines are healthy is our number one priority. Throughout my career in veterinary
0
1
1
Utilizing the Nu.Q® Vet Cancer Test in Practice webinar TOMORROW Sue Ettinger, DVM, DACVIM aka Dr Sue Cancer Vet, will walk you through the science behind our Nu.Q® Vet Cancer Test and how you can apply it in daily practice. 💪Earn 0.50 CE 🔗Register:
0
0
0
Day 2 at ISOBM 2025: presenting 'Glioblastoma Diagnosis and Monitoring through Nucleosome Epigenetic Modifications Tracking' Download here:
0
0
0
Day 1 at ISOBM 2025, and we presented our first poster: Detection of Early Stage I/II Cancer by Immunoassay of Crosslinked Plasma Cell Free Nucleosomes Download from our website:
0
0
1
Point-of-Care Quantification of H3.1-Nucleosomes in Fresh Whole Blood: A Novel Tool For NETs Measurement In Hospital Setting: poster now on the website. Download here:
0
0
0
Join us for a webinar next Thursday! Sue Ettinger, DVM, DACVIM aka Dr Sue Cancer Vet, will walk you through the science behind our Nu.Q® Vet Cancer Test and how you can apply it in daily practice. 💪Earn 0.50 RACE-approved CE credit. 🔗Register: https://t.co/c5p6Ei8asT
0
0
0
Webinar this Wednesday: Beyond the Genome: Measuring Epigenetic Modifications Across Matrices for Biomarker and Drug Discovery 📅Date : Wednesday October 8 ⌚8am PT / 11am ET / 5pm CET Speakers: Dr Eric Ariazi and Dr Marielle Herzog Sign up:
0
0
0
Join our webinar: Beyond the Genome: Measuring Epigenetic Modifications Across Matrices for Biomarker and Drug Discovery 📅Date : Wednesday October 8 ⌚8am PT / 11am ET / 5pm CET Speakers: Dr Eric Ariazi and Dr Marielle Herzog Sign up:
0
0
1
NEWS: Volition Signs Co-Marketing and Services Agreement with Hologic Diagenode. Find out more in our press release:
0
2
4
Upcoming GenomeWeb Webinar | October 8 🔬 Topic: How epigenetic profiling & histone modifications are shaping the future of cancer research, biomarker discovery, and therapy. 🎙️ Speakers: Eric Ariazi & Marielle Herzog 👉 Save your spot:
0
0
1
Sepsis affects 245,000 people in the UK annually, claiming 48,000 lives.
Sepsis can be life-threatening, but knowing the signs can save lives. Symptoms differ in adults, children, & infants under 5. Learn more: https://t.co/kvKqriFS6D
1
7
8
This #SepsisAwarenessMonth, we sat down with our Chief Medical Officer, Dr. Andrew Retter, to talk about the evolution of intensive care, the challenges healthcare professionals face when diagnosing sepsis, and the innovations that could transform patient outcomes. Read now:
0
0
0
#ICYMI: Volition signed its first human out licensing deal, a research license and exclusive commercial option rights agreement for Antiphospholipid Syndrome (“APS”) with Werfen’s Immunoassay Technology Center, a worldwide leader in specialized diagnostics. Find out more:
0
1
4